US v. Teva Pharmaceuticals USA, Inc., et al

Track this case

Case Number:

23-8028

Court:

Appellate - 1st Circuit

Nature of Suit:

Companies

Sectors & Industries:

  1. February 26, 2024

    Teva Tells 1st Circ. Feds Must Clear High Bar In FCA Case

    Teva Pharmaceuticals told the First Circuit on Monday that the federal government should be held to — and cannot meet — a strict causation standard in a False Claims Act kickback case, asking the court to settle a matter of first impression in the circuit.

  2. January 01, 2024

    Appellate Outlook: Circuit Splits & Hot Topics To Track In 2024

    The 2024 appellate almanac is looking lively after eye-popping opinions and arguments in 2023's homestretch. As the new year begins, several circuit splits seem more serious, ideological imbalances are in the spotlight, and luminaries of the U.S. Supreme Court bar are locked in a burgeoning battle over alleged corporate complicity in terrorism.

  3. November 17, 2023

    1st Circ. To Review Crucial Issue In Teva, Regeneron Cases

    The First Circuit on Friday granted Teva Pharmaceutical's request to settle how rigorous the causation standard should be in federal False Claims Act kickback cases, a legal issue that has previously led to circuit splits and divergent rulings.